Login to Your Account

American College of Cardiology

Vivus, Orexigen Jump on CV Data, but No Obesity Win Yet

By Jennifer Boggs

Tuesday, April 5, 2011
Cardiovascular data presented for obesity candidates Qnexa (phentermine/topiramate) and Contrave (naltrexone/bupropion) at the American College of Cardiology (ACC) meeting in New Orleans might have boosted shares of Vivus Inc. and Orexigen Therapeutics Inc. Monday, but those results are unlikely to ease the path to approval for either drug.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription